Companies / Dyne Therapeutics, Inc. / Activity
Activity — Dyne Therapeutics, Inc.
26 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Kersten Dirk Director | Sell | Common Stock | $5.58M | -282K -5.57% | 4,774,058 2.56% of shares | medium |
| Mar 10, 2026 | Kersten Dirk Director | Sell | Common Stock | $4.25M | -220K -4.17% | 5,055,916 2.71% of shares | medium |
| Mar 9, 2026 | Kersten Dirk Director | Sell | Common Stock | $3.15M | -178K -3.25% | 5,285,156 2.83% of shares | medium |
| Mar 11, 2026 | Kersten Dirk Director | Sell | Common Stock | $2.53M | -130K -2.72% | 4,644,386 2.49% of shares | medium |
| Mar 10, 2026 | Kersten Dirk Director | Sell | Common Stock | $172.7K | -9K -0.18% | 5,275,674 2.83% of shares | medium |
| Mar 6, 2026 | Posner Brian S Director | Buy | Common Stock | $45.2K | +3K +35.29% | 11,500 <0.01% of shares | low |
| Jun 3, 2026 | Posner Brian S Director | Buy | Common Stock | $43.7K | +3K +12.50% | 22,500 0.01% of shares | low |
| May 20, 2026 | Posner Brian S Director | Buy | Common Stock | $42.8K | +3K +16.13% | 18,000 <0.01% of shares | low |
| Mar 5, 2026 | Cox John CEO | Sell | Common Stock | $40.7K | -3K -0.72% | 374,145 0.20% of shares | low |
| Mar 11, 2026 | Posner Brian S Director | Buy | Common Stock | $38.7K | +2K +17.39% | 13,500 <0.01% of shares | low |
| May 26, 2026 | Posner Brian S Director | Buy | Common Stock | $36.4K | +2K +11.11% | 20,000 0.01% of shares | low |
| Mar 30, 2026 | Posner Brian S Director | Buy | Common Stock | $34.2K | +2K +14.81% | 15,500 <0.01% of shares | low |
| Jun 8, 2026 | Posner Brian S Director | Buy | Common Stock | $33.9K | +2K +8.89% | 24,500 0.01% of shares | low |
| Mar 5, 2026 | Kerr Douglas Executive | Sell | Common Stock | $13.5K | -904 -0.52% | 171,606 0.09% of shares | low |
| Mar 5, 2026 | Friedl-Naderer Johanna Executive | Sell | Common Stock | $2.2K | -148 -0.10% | 154,581 0.08% of shares | low |
| Feb 12, 2026 | Cox John CEO | Grant | Common Stock | $0 | +180K +91.43% | 376,877 0.20% of shares | low |
| Feb 12, 2026 | Kerr Douglas Executive | Grant | Common Stock | $0 | +85K +97.13% | 172,510 0.09% of shares | low |
| Feb 12, 2026 | Friedl-Naderer Johanna Executive | Grant | Common Stock | $0 | +60K +63.34% | 154,729 0.08% of shares | low |
| Feb 12, 2026 | Lucera Erick Executive | Grant | Common Stock | $0 | +65K +98.34% | 131,100 0.07% of shares | low |
| Jun 5, 2026 | Posner Brian S Director | Grant | Stock option (right to buy) | — | +35K | 35,152 0.02% of shares | low |
| Jun 22, 2026 | Greene Barry E Director | Grant | Stock option (right to buy) | — | +57K | 57,463 0.03% of shares | low |
| Jun 5, 2026 | Hurwitz Edward Director | Grant | Stock option (right to buy) | — | +35K | 35,152 0.02% of shares | low |
| Feb 12, 2026 | Cox John CEO | Grant | Stock option (right to buy) | — | +285K | 285,000 0.15% of shares | low |
| Feb 12, 2026 | Kerr Douglas Executive | Grant | Stock option (right to buy) | — | +130K | 130,000 0.07% of shares | low |
| Feb 12, 2026 | Friedl-Naderer Johanna Executive | Grant | Stock option (right to buy) | — | +90K | 90,000 0.05% of shares | low |
| Feb 12, 2026 | Lucera Erick Executive | Grant | Stock Option (Right to Buy) | — | +105K | 105,000 0.06% of shares | low |